Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 02, 2015 9:26 PM ET

Healthcare Providers and Services

Company Overview of DIATHERIX Laboratories, Inc.

Company Overview

DIATHERIX Laboratories, Inc., a molecular diagnostic laboratory, offers diagnostic services for detection of infectious diseases. It uses target enriched multiplex polymerase chain reaction technology for precise detection of infectious diseases. The company provides nucleic acid extraction, template addition, and hybridization services. It offers its services to physicians and hospitals. DIATHERIX Laboratories, Inc. was incorporated in 2007 and is based in Huntsville, Alabama.

601 Genome Way

Suite 4208

Huntsville, AL 35806

United States

Founded in 2007

Phone:

256-327-0699

Fax:

256-327-0984

Key Executives for DIATHERIX Laboratories, Inc.

Chairman and Chief Executive Officer
Age: 59
President and Chief Operating Officer
Laboratory Director
Compensation as of Fiscal Year 2015.

DIATHERIX Laboratories, Inc. Key Developments

DIATHERIX Laboratories, Inc. Appoints Ruth W. Brinkley to its Board of Directors

DIATHERIX Laboratories, Inc. announced the appointment of Ruth W. Brinkley, FACHE, to its board of directors. Brinkley has more than 40 years of healthcare experience working in private, public, academic, community-based and healthcare organizations. She currently serves as president and chief executive officer of KentuckyOne Health and as senior vice president of operations for Catholic Health Initiatives.

DIATHERIX Laboratories, Inc. Receives Second Research Contract from FDA and HHS

DIATHERIX Laboratories, Inc. has been awarded a second federal contract to continue its work in the development of research methodologies designed to support the development of diagnostic tools to detect certain low prevalence pathogens. The contract is a joint award from the Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) to support the development of diagnostic devices/platforms to detect high priority pathogens, as classified by the National Institute of Allergy and Infectious Diseases (NIAID). Diatherix's research focuses on three NIAID pathogens: Francisella tularensis, Escherichia coli, and Babesia microti. Though not prevalent in the natural environment, the pathogens are prioritized by NIAID because of the ease with which they can be disseminated or transmitted; the mortality rates and public health impact they can generate; their potential to cause public panic and social disruption; and the special actions that are required for public health preparedness. For instance, F. tularensis has a low infectious dose, is highly virulent, and is easily spread by aerosol; as such, it is classified by the NIAID and the U.S. Department of Homeland Security as a Category A Priority pathogen/biological agent that poses high risk to national security and public health. The low prevalence of these pathogens complicates the development of diagnostic tools to aid in their detection, as sufficient clinical samples may not be available to conduct the clinical sensitivity studies required for Food and Drug Administration (FDA) clearance. To address this regulatory and scientific challenge, the FDA is exploring the use of "spiked" clinical samples special lab samples in which the pathogen being studied is introduced at increased or enriched levels to support sensitivity studies for the evaluation of diagnostic devices.

Luminex Corp. Claims Diatherix's Infringed on Patent

Luminex Corp. is claiming that Diatherix, is infringing on its patents for rapid testing of a number of medical conditions. A lawsuit filed by Luminex Corp. argues that Diatherix has infringed on three of its patents that are connected with Luminex’s patented xMAP technology, which the company says is capable of performing at least 500 tests on a single sample. Diatherix and its CEO Frank Grimaud are named in the lawsuit. Efforts to obtain a comment from the company were not immediately successful. In the complaint, Luminex alleges Diatherix and Grimaud were familiar with the Luminex patents. Luminex contends the Diatherix violated at least one claim in each of three U.S. patents. The lawsuit also alleges breach of contract and seeks unspecified damages and an order barring Diatherix and its employees from use of the patents.

Similar Private Companies By Industry

Company Name Region
Jawach Inc. United States
Trident Laboratories, Inc. United States
Tree City Dialysis, LLC United States
HelpMed, Inc. United States
Emergency Consultants, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
June 1, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIATHERIX Laboratories, Inc., please visit www.diatherix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.